Core Viewpoint - The new regulations from the National Medical Products Administration (NMPA) will lead to the elimination of a significant number of traditional Chinese medicine (TCM) products from the market, with over 70% of existing approvals facing potential cancellation due to safety information issues [2][11]. Regulatory Changes - The "death clause" for TCM, effective from July 1, 2023, mandates that any product with unclear safety information in its instructions will not be re-registered after three years [2]. - The NMPA has already begun revising product instructions, requiring core safety information to be added to many commonly used TCM products [4]. - A new regulation on TCM production supervision will take effect on March 1, 2026, raising industry entry barriers and imposing stricter requirements on the entire supply chain [4]. Industry Impact - The TCM industry is experiencing a stark divide, with leading companies like Baiyunshan generating revenues of 61.606 billion yuan, while smaller firms struggle with revenues around 6 million yuan [6]. - The cost of compliance for smaller firms is substantial, with estimates suggesting that a traditional TCM product may require an investment of 20 million yuan over three years to meet safety data requirements [6]. - Major companies are proactively streamlining their product lines and focusing on core products, while many smaller firms are left with difficult choices regarding their market presence [6][12]. Market Dynamics - The regulatory changes are expected to lead to a significant consolidation in the TCM market, with predictions that 30% to 40% of TCM approvals may exit the market within the next 3 to 5 years [11][12]. - The dual approach of price regulation and re-registration requirements is tightening the market for low-quality TCM products, further reducing their viability [9][10]. - The future TCM market will likely see increased entry barriers, with only products demonstrating clinical value being supported by insurance [12]. Strategic Responses - Companies are advised to focus on three main strategies: conducting real-world studies to support safety data, applying for new drug status for promising products, and voluntarily canceling low-value approvals [12]. - The industry is expected to prioritize quality over quantity, with a shift towards products that can withstand scientific scrutiny and meet patient needs [12].

Core Viewpoint - The article discusses the impending regulatory changes in the Chinese traditional medicine sector, particularly the "death clause" for traditional Chinese medicine (TCM) products, which will lead to the elimination of over 70% of existing TCM approvals due to safety information issues by July 2026 [1][4]. Regulatory Changes - The National Medical Products Administration (NMPA) has implemented a new regulation that will not allow re-registration of TCM products if any safety information in their instructions remains "unclear" after three years from July 1, 2023 [1][4]. - As of 2025, multiple announcements have been made requiring TCM products to supplement core safety information, indicating a shift towards stricter regulatory compliance [3]. Industry Impact - The regulatory changes are expected to create a significant divide in the industry, with leading companies like Baiyunshan generating revenues of 61.606 billion yuan, while smaller firms struggle with revenues around 6 million yuan [4]. - The cost of compliance for smaller firms is estimated to be around 20 million yuan over three years, which could deplete their profits, while larger firms have the resources to manage these costs effectively [4]. Market Dynamics - The article predicts that 30% to 40% of TCM approvals will exit the market in the next 3-5 years, leading to a more concentrated market where only high-quality products with clinical value will survive [6][8]. - The regulatory framework is pushing for a transition from quantity to quality in the TCM industry, with a focus on clinical value and scientific evidence [8]. Strategic Responses - Companies are advised to focus on three main strategies: conducting real-world studies to supplement safety data, applying for new drug status for promising products, and voluntarily canceling low-value approvals to concentrate on core products [8]. - The future market will see increased entry barriers, with only products that demonstrate safety and clinical value being supported by insurance and procurement channels [8].

Core Viewpoint - The new regulations from the National Medical Products Administration (NMPA) regarding traditional Chinese medicine (TCM) registration are set to significantly impact the industry, with over 70% of existing TCM products potentially facing elimination due to safety information issues in their labeling [1][5]. Regulatory Changes - The "death clause" in the new regulations mandates that any TCM product with unclear safety information in its labeling will not be approved for re-registration after July 1, 2026 [1]. - The NMPA has already begun implementing these regulations, requiring several commonly used TCM products to supplement core safety information for re-registration [2]. - A new set of regulations for TCM production supervision will take effect on March 1, 2026, raising industry entry barriers and imposing stricter requirements on the entire supply chain [2]. Industry Dynamics - The TCM industry is experiencing a stark divide between leading enterprises and smaller firms, with significant revenue disparities; for instance, the top company, Baiyunshan, reported revenues of 61.606 billion yuan, while smaller firms averaged around 6 million yuan [3]. - The cost of compliance for smaller firms is substantial, with estimates suggesting that a traditional TCM product may require an investment of at least 20 million yuan over three years to meet safety data requirements [3]. - Leading companies like Yunnan Baiyao and Tongrentang are proactively streamlining their product lines and focusing on core products backed by clinical data, while many smaller firms are left with limited options [3][4]. Market Trends - The regulatory changes are expected to lead to a significant increase in industry concentration, with predictions that leading firms will retain over 70% of their core products, while mid-tier companies may lose half of their approvals within two years [4]. - A nationwide price regulation initiative is underway, targeting low-quality TCM products and establishing minimum treatment costs for various medications [4]. - The dual approach of safety data requirements and price regulation is anticipated to further compress the market for low-quality TCM products, pushing the industry towards a focus on quality over quantity [5]. Strategic Responses - TCM companies are advised to pursue three main strategies: conducting real-world studies to enhance safety data, reclassifying promising products as improved new drugs, and voluntarily canceling low-value approvals to concentrate on core offerings [6]. - The future TCM market is expected to see heightened entry barriers, with products lacking safety data losing market access, and reimbursement mechanisms favoring clinically valuable products [6]. - The ongoing regulatory overhaul is viewed as an opportunity for the industry to shed low-quality products and focus on those that can withstand scientific scrutiny and gain patient trust [6].

Core Insights - The recent price governance actions on traditional Chinese medicine (TCM) have become less public, with many provinces opting for closed-door processes to handle pricing issues [1][2][9] - The high pricing of TCM has been a long-standing issue, with previous studies indicating that a significant number of TCM products are overpriced [4][5] - The ongoing price governance is expected to lead to a significant industry reshuffle, with many companies facing financial pressures due to continuous price cuts and declining market demand [10][11] Group 1: Price Governance Actions - Various provinces have initiated price governance for TCM, but details are often not disclosed publicly, requiring companies to log in to access specific information [1][2][9] - The price governance actions were prompted by public outcry over the high costs of TCM compared to Western medicine, revealing significant price discrepancies [2][4] Group 2: Industry Challenges - The TCM industry is experiencing financial difficulties, with a reported total revenue of 356.19 billion yuan for 75 listed TCM companies in 2024, a decrease of 4.6% year-on-year [10] - Major TCM companies, such as Pien Tze Huang and China Resources Sanjiu, have reported declines in revenue and net profit, indicating a challenging market environment [10][11] - The National Medical Insurance Administration plans to expand drug procurement alliances by 2025, which will further pressure TCM prices and potentially lead to the elimination of less competitive companies [12][13] Group 3: Future Outlook - The ongoing price governance and procurement reforms are expected to create downward pressure on TCM prices, leading to a necessary industry restructuring [13] - Despite the challenges, there remains potential for high-quality TCM companies to be revalued positively after the industry undergoes a transformation towards product-driven strategies [13]